Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

GMAB

Genmab ADR

Oct 24 • 04:00PM ET

29.89

+0.02 0.07 %

Healthcare • Biotechnology • Denmark • NASD

Peers: AZN JNJ BMY GSK LLY PFE MRK NVS REGN AMGN

| Held by: IBB FBT AVDE FWD FENI CANC FTQI APIE DFAI RGLO

Scroll to Statements

Index	-	P/E	14.92	EPS (ttm)	2.00	Insider Own	0.00%	Shs Outstand	615.55M	Perf Week	-9.89%
Market Cap	18.40B	Forward P/E	17.78	EPS next Y	1.68	Insider Trans	-	Shs Float	615.55M	Perf Month	3.64%
Enterprise Value	15.65B	PEG	1.66	EPS next Q	0.48	Inst Own	10.47%	Short Float	0.90%	Perf Quarter	29.45%
Income	1.27B	P/S	5.43	EPS this Y	2.10%	Inst Trans	0.37%	Short Ratio	3.06	Perf Half Y	45.17%
Sales	3.39B	P/B	3.47	EPS next Y	-2.44%	ROA	21.17%	Short Interest	5.56M	Perf YTD	43.22%
Book/sh	8.62	P/C	6.35	EPS next 5Y	8.98%	ROE	26.08%	52W High	33.65 -11.17%	Perf Year	31.27%
Cash/sh	4.71	P/FCF	18.30	EPS past 3/5Y	34.34% 28.01%	ROIC	23.40%	52W Low	17.24 73.43%	Perf 3Y	-17.82%
Dividend Est.	-	EV/EBITDA	12.58	Sales past 3/5Y	32.30% 31.15%	Gross Margin	94.45%	Volatility	2.23% 2.37%	Perf 5Y	-17.45%
Dividend TTM	-	EV/Sales	4.62	EPS Y/Y TTM	64.46%	Oper. Margin	34.76%	ATR (14)	0.83	Perf 10Y	244.59%
Dividend Ex-Date	-	Quick Ratio	6.20	Sales Y/Y TTM	23.25%	Profit Margin	37.52%	RSI (14)	45.20	Recom	1.77
Dividend Gr. 3/5Y	- -	Current Ratio	6.22	EPS Q/Q	76.63%	SMA20	-5.74%	Beta	0.97	Target Price	33.84
Payout	0.00%	Debt/Eq	0.03	Sales Q/Q	20.16%	SMA50	4.20%	Rel Volume	2.15	Prev Close	29.87
Employees	2682	LT Debt/Eq	0.02	Earnings	Aug 07 AMC	SMA200	30.56%	Avg Volume	1.82M	Price	29.89
IPO	Jun 01, 2009	Option/Short	Yes / Yes	EPS/Sales Surpr.	35.74% 2.29%	Trades		Volume	3,904,389	Change	0.07%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-23-25	Upgrade	Guggenheim	Neutral → Buy	$43
Apr-01-25	Downgrade	Bernstein	Mkt Perform → Underperform
Mar-11-25	Upgrade	William Blair	Mkt Perform → Outperform
Feb-13-25	Upgrade	Leerink Partners	Market Perform → Outperform	$27
Oct-08-24	Initiated	Redburn Atlantic	Buy
Sep-04-24	Resumed	Morgan Stanley	Equal-Weight	$31
Aug-20-24	Downgrade	JP Morgan	Overweight → Neutral
Jul-15-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Feb-23-24	Upgrade	BMO Capital Markets	Market Perform → Outperform	$46 → $48
Jan-22-24	Downgrade	Citigroup	Neutral → Sell
Dec-06-23	Upgrade	UBS	Neutral → Buy
Nov-10-23	Upgrade	Deutsche Bank	Hold → Buy
Nov-08-23	Upgrade	DNB Markets	Sell → Buy
Oct-18-23	Initiated	Exane BNP Paribas	Underperform
Sep-06-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Aug-24-23	Initiated	BTIG Research	Buy	$44
Jul-14-23	Initiated	HSBC Securities	Buy
May-31-23	Initiated	UBS	Neutral
May-12-23	Initiated	Morgan Stanley	Underweight
Dec-20-22	Downgrade	Citigroup	Buy → Neutral

Show Previous Ratings

Oct-14-25 11:40AM	GMAB or TECH: Which Is the Better Value Stock Right Now? (Zacks)
Oct-10-25 12:19PM	Bristol Myers Squibb Buys Private Biotech for $1.5 Billion. The Deal Wave Keeps Going. (Barrons.com)
Oct-06-25 09:50AM	GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal (Zacks)
Oct-03-25 05:29PM	Why Genmab Stock Popped on Friday (Motley Fool)
12:00PM	What Makes Genmab A/S Sponsored ADR (GMAB) a Strong Momentum Stock: Buy Now? (Zacks)
10:00AM	Loading…
10:00AM	Best Momentum Stock to Buy for October 3rd (Zacks)
02:49AM	New Strong Buy Stocks for October 3rd (Zacks)
Sep-30-25 03:43PM	Why Genmab Stock Was Marching Higher Today (Motley Fool)
Sep-29-25 04:25PM	Genmab Strikes $8 Billion Deal To Acquire Cancer-Focused Merus (Investor's Business Daily)
07:36AM	This Dutch Drugmaker's Stock Is Jumping 38%. Here's Why It's Being Acquired. (Barrons.com)
06:07AM	Premarket movers: Merus, GSK, Novo Nordisk (MarketWatch)
05:34AM	Months after cancer drug trial, Merus agrees to be bought at 41% premium (MarketWatch)
02:26AM	Genmab to Buy Cancer-Treatment Developer Merus For $8 Billion in Cash (The Wall Street Journal)
01:14AM	Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model (Business Wire)
Sep-17-25 02:27PM	Bernstein Reiterates a Sell Rating on Genmab A/S (GMAB) (Insider Monkey)
11:14AM	Loading…
Sep-11-25 11:14AM	Genmab A/S (GMAB) Scores FDA Breakthrough for Rina-S (Insider Monkey)
Sep-03-25 08:30AM	Genmab Announces Updated Results from Phase 2 EPCORE NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) (Business Wire)
Aug-29-25 05:12AM	Genmab A/S (GMAB)'s Epcoritamab Delivers 95% Response in Lymphoma (Insider Monkey)
05:02AM	Genmab A/S (GMAB) Expands Tivdak and Epkinly Commercial Push Globally (Insider Monkey)
Aug-26-25 08:00AM	Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S) in Advanced Endometrial Cancer (EC) (Business Wire)
Aug-12-25 02:36PM	Capital Increase in Genmab as a Result of Employee Warrant Exercise (GlobeNewswire)
09:11AM	William Blair Remains Bullish on Genmab A/S (GMAB) (Insider Monkey)
Aug-08-25 12:47PM	IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi (Zacks) -5.55%
09:55AM	Wall Street Analysts Believe Genmab (GMAB) Could Rally 33.8%: Here's is How to Trade (Zacks)
03:29AM	Genmab AS (GMAB) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic Advancements (GuruFocus.com)
Aug-07-25 12:48PM	Genmab raises full-year outlook, shares rise (Investing.com) +5.49%
11:14AM	NVAX Stock Gains on Q2 Earnings & Sales Beat, Ups '25 Sales View (Zacks)
11:08AM	Genmab Announces Financial Results for the First Half of 2025 (GlobeNewswire)
10:31AM	Genmab Announces Phase 3 EPCORE FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) (Business Wire)
Aug-06-25 11:07AM	Perrigo Beats on Q2 Earnings & Sales, Stock Down on '25 Sales View Cut (Zacks)
09:22AM	Loading…
09:22AM	JAZZ Stock Down on Wider-Than-Expected Q2 Loss, '25 Sales View Cut (Zacks)
Aug-05-25 11:54AM	CRSP Stock Down on Huge Q2 Loss, Focus on Increasing Casgevy Adoption (Zacks)
10:17AM	BioMarin Beats on Q2 Earnings & Sales, Stock Gains on Raised '25 View (Zacks)
Aug-04-25 11:07AM	Sarepta to Report Q2 Earnings: What's in Store for the Stock? (Zacks)
09:51AM	Bio-Techne Q4 Earnings Preview: What's in Store for the Stock? (Zacks)
Aug-01-25 11:40AM	GMAB vs. ACAD: Which Stock Is the Better Value Option? (Zacks)
Jul-28-25 02:07AM	TD Cowen Maintains a Hold on Genmab A/S (GMAB) (Insider Monkey)
Jul-25-25 10:37PM	Genmab A/S (GMAB) Opens U.S. Hub in New Jersey to Drive Global Growth (Insider Monkey)
Jul-24-25 11:47PM	Truist Securities Hikes Genmab A/S (GMAB) Price Target Buoyed by Revenue Outlook (Insider Monkey)
Jul-23-25 01:18PM	Will Escalating Medical Costs Dampen Centene's Q2 Earnings? (Zacks)
Jul-22-25 01:30PM	Tenet Beats Q2 Earnings on Strong Patient Volumes, Hikes '25 EPS View (Zacks)
12:00PM	Genmab (GMAB) Upgraded to Strong Buy: Here's Why (Zacks)
09:55AM	Wall Street Analysts See a 39.97% Upside in Genmab (GMAB): Can the Stock Really Move This High? (Zacks)
Jul-16-25 06:29AM	Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2025 (GlobeNewswire)
Jul-10-25 11:14AM	UBS Maintains a Buy on Genmab (GMAB) With a DKK2,500 PT (Insider Monkey)
08:08AM	Genmab (GMAB) Announced Results From its EPCORE NHL-2 Trial (Insider Monkey)
Jul-03-25 08:19AM	M.Stanley takes neutral stance on Genmab ahead of portfolio, execution updates (Investing.com)
Jul-01-25 08:00AM	Genmab Announces Changes to its Executive Committee (GlobeNewswire)
Jun-30-25 09:30AM	Completion of Share Buy-back Program (GlobeNewswire)
Jun-23-25 08:19AM	Transactions in Connection with Share Buy-back Program (GlobeNewswire)
Jun-17-25 01:34PM	Capital Increase in Genmab as a Result of Employee Warrant Exercise (GlobeNewswire)
11:37AM	Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons (GlobeNewswire)
Jun-16-25 09:28AM	Transactions in Connection with Share Buy-back Program (GlobeNewswire)
Jun-15-25 05:00AM	Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT) (GlobeNewswire)
Jun-12-25 01:08PM	Grant of Restricted Stock Units and Warrants to Employees in Genmab (GlobeNewswire)
Jun-10-25 07:23AM	Transactions in Connection with Share Buy-back Program (GlobeNewswire)
Jun-02-25 06:49PM	Why Genmab Stock Smashed It on Monday (Motley Fool)
02:30PM	Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL-01 Trial (GlobeNewswire)
08:03AM	Transactions in Connection with Share Buy-back Program (GlobeNewswire)
May-31-25 02:14PM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
May-30-25 09:05AM	Genmab price target lowered to DKK 2,000 from DKK 2,300 at RBC Capital (TipRanks)
May-27-25 09:55AM	Genmab to Participate in a Fireside Chat at the 46th Goldman Sachs Annual Global Healthcare Conference (GlobeNewswire)
May-26-25 08:30AM	Transactions in Connection with Share Buy-back Program (GlobeNewswire)
May-23-25 01:49AM	Genmab A/S (GMAB) Unveils Promising Rina-S and Epcoritamab Data at ASCO 2025 (Insider Monkey)
May-22-25 05:05PM	Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (Business Wire)
May-21-25 10:02AM	Genmab to Participate in a Fireside Chat at the 2025 Jefferies Global Health Care Conference (GlobeNewswire)
May-20-25 12:01PM	Capital Increase in Genmab as a Result of Employee Warrant Exercise (GlobeNewswire)
May-19-25 09:08AM	Transactions in Connection with Share Buy-back Program (GlobeNewswire)
May-14-25 10:15AM	Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY) Development Program at the 2025 European Hematology Association (EHA) Congress (Business Wire)
May-12-25 08:51AM	Transactions in Connection with Share Buy-back Program (GlobeNewswire)
May-08-25 11:01AM	Genmab Announces Financial Results for the First Quarter of 2024 (GlobeNewswire) -5.73%
May-05-25 08:23AM	Transactions in Connection with Share Buy-back Program (GlobeNewswire)
May-01-25 08:24PM	Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL) (Business Wire)
03:31AM	Is Genmab A/S (GMAB) the Most Profitable Growth Stock to Buy Now? (Insider Monkey)
Apr-28-25 08:16AM	Transactions in Connection with Share Buy-back Program (GlobeNewswire)
Apr-27-25 11:40PM	Why AbbVie's Stock Is A Strong Buy After Q1 2025 Results (Seeking Alpha)
Apr-24-25 07:46AM	Johnson & Johnson Just Proved The Bears Wrong Again (Seeking Alpha)
Apr-22-25 07:23AM	Transactions in Connection with Share Buy-back Program (GlobeNewswire)
Apr-20-25 11:28AM	IDNA: The Cutting Edge Of Medical Science Is A Risky Investment (Seeking Alpha)
Apr-16-25 11:40AM	GMAB or RGEN: Which Is the Better Value Stock Right Now? (Zacks)
09:40AM	Should Value Investors Buy Genmab (GMAB) Stock? (Zacks)
Apr-15-25 07:36AM	Genmab's Outlook Beyond Darzalex's Patent Cliff (Seeking Alpha)
06:22AM	Genmab Announces Net Sales of DARZALEX (daratumumab) for First Quarter of 2025 (GlobeNewswire)
Apr-14-25 08:42AM	Transactions in Connection with Share Buy-back Program (GlobeNewswire)
Apr-10-25 12:20PM	Genmab A/S Share Capital Reduction (GlobeNewswire)
Apr-07-25 07:43AM	Transactions In Connection with Share Buy-back Program (GlobeNewswire)
Apr-02-25 09:47AM	Is Genmab A/S (GMAB) d The Most Profitable Biotech Stock To Buy Right Now? (Insider Monkey)
Apr-01-25 03:53PM	Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons (GlobeNewswire)
10:00AM	Is Genmab A/S (GMAB) the Most Undervalued Healthcare Stock to Buy According to Analysts? (Insider Monkey)
Mar-31-25 11:20AM	TIVDAK (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer (GlobeNewswire)
08:18AM	Transactions in connection with share buy-back program (GlobeNewswire)
Mar-27-25 08:00AM	TIVDAK (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy (Business Wire)
Mar-25-25 05:28PM	Genmab Announces Initiation of Share Buy-Back Program (GlobeNewswire)
Mar-21-25 11:29PM	Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc. (GlobeNewswire)
Mar-17-25 12:19PM	Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer (GlobeNewswire)
Mar-12-25 02:19PM	Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons (GlobeNewswire)
02:13PM	Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab (GlobeNewswire)
10:23AM	Passing of Genmab A/S Annual General Meeting (GlobeNewswire)
Mar-11-25 10:20AM	Genmab says J&J not exercising option on HexaBody-CD38 (TipRanks) -7.80%
Mar-10-25 10:21AM	Genmab Announces Johnson & Johnson Decision Regarding HexaBody-CD38 (Business Wire) -8.97%

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Klimovsky Judith V	Director	Jun 17 '25	Proposed Sale	51.69	1,300	67,200		Jun 17 02:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GMAB

Genmab ADR

Upgrade your FINVIZ experience